Black Diamond Therapeutics Inc [BDTX] stock is trading at $2.31, up 19.69%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BDTX shares have gain 5.00% over the last week, with a monthly amount drifted -5.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on July 31, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $20. On June 30, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $11 on June 28, 2023. Wedbush upgraded its rating to a Outperform but $10 remained the price target by the analyst firm on June 27, 2023. Wedbush downgraded its rating to Neutral for this stock on March 29, 2022. In a note dated March 22, 2022, H.C. Wainwright downgraded an Neutral rating on this stock.
Black Diamond Therapeutics Inc [BDTX] stock has fluctuated between $1.91 and $7.66 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $2.31 at the most recent close of the market. An investor can expect a potential return of 765.8% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -16.62%, Pretax Profit Margin comes in at -14.94%, and Net Profit Margin reading is -14.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.68 and Total Capital is -0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.1000 points at the first support level, and at 1.8800 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.6000, and for the 2nd resistance point, it is at 2.8800.
Ratios To Look Out For
For context, Black Diamond Therapeutics Inc’s Current Ratio is 5.55. Further, the Quick Ratio stands at 5.55, while the Cash Ratio is 1.13.
Transactions by insiders
Recent insider trading involved Versant Venture Capital VI, L., 10% Owner, that happened on Aug 28 ’24 when 0.22 million shares were sold. Former Employer, David Epstein completed a deal on Jul 31 ’24 to buy 50000.0 shares. Meanwhile, Former Employee David Epstein bought 50000.0 shares on Jul 26 ’24.
